IART icon

Integra LifeSciences

14.27 USD
-0.59
3.97%
At close Aug 25, 4:00 PM EDT
After hours
14.27
+0.00
0.00%
1 day
-3.97%
5 days
1.57%
1 month
8.85%
3 months
8.77%
6 months
-42.27%
Year to date
-38.01%
1 year
-31.92%
5 years
-69.70%
10 years
-51.84%
 

About: Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Employees: 4,396

0
Funds holding %
of 7,429 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

16% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 63

1.35% less ownership

Funds ownership: 95.18% [Q1] → 93.83% (-1.35%) [Q2]

6% less funds holding

Funds holding: 218 [Q1] → 204 (-14) [Q2]

18% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 44

45% less capital invested

Capital invested by funds: $1.62B [Q1] → $895M (-$722M) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

Research analyst outlook

We haven’t received any recent analyst ratings for IART.

Financial journalist opinion

Based on 5 articles about IART published over the past 30 days

Neutral
Seeking Alpha
3 weeks ago
Integra LifeSciences Holdings Corporation (IART) Q2 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Executives Christopher Ward – Senior Director of Investor Relations Lea Daniels Knight – Executive VP & CFO Mojdeh Poul – President, CEO & Director Analysts Lilia-Celine Breton Lozada - JPMorgan Chase & Co, Research Division Ravi Misra - Truist Securities, Inc., Research Division Unknown Analyst Vikramjeet Singh Chopra - Wells Fargo Securities, LLC, Research Division Xuyang Li - Jefferies LLC, Research Division Operator Good day, and thank you for standing by. Welcome to the Integra LifeSciences Second Quarter 2025 Financial Results Call.
Integra LifeSciences Holdings Corporation (IART) Q2 2025 Earnings Call Transcript
Neutral
The Motley Fool
3 weeks ago
Integra (IART) Q2 Revenue Beats by 5%
Integra (IART) Q2 Revenue Beats by 5%
Integra (IART) Q2 Revenue Beats by 5%
Positive
Zacks Investment Research
3 weeks ago
Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics
Positive
Zacks Investment Research
3 weeks ago
Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.63 per share a year ago.
Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates
Neutral
GlobeNewsWire
3 weeks ago
Integra LifeSciences Reports Second Quarter 2025 Financial Results
PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025.
Integra LifeSciences Reports Second Quarter 2025 Financial Results
Neutral
GlobeNewsWire
1 month ago
Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025
PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2025 financial results on Thursday, July 31, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.
Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025
Positive
Zacks Investment Research
1 month ago
IART Stock May Rise on First Enrollment in AERA Pediatric Registry
Integra enrolls first pediatric patient in AERA registry to evaluate real-world use of its ETBD system and expand ENT market presence.
IART Stock May Rise on First Enrollment in AERA Pediatric Registry
Neutral
GlobeNewsWire
1 month ago
Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry
PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first patient in the Acclarent AERA Pediatric Registry, a prospective, multi-center observational registry evaluating the real-world use of the AERA Eustachian Tube Balloon Dilation System in children.
Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry
Neutral
PRNewsWire
2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
Neutral
GlobeNewsWire
2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART
Charts implemented using Lightweight Charts™